Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04665765 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04665765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 18, 2021
Completion date
June 28, 2027
Enrollment
41 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma unclassifiable, recurrent diffuse large b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, recurrent transformed b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell cell lymphoma, refractory transformed b-cell non-hodgkin lymphoma